These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8787077)

  • 21. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cloning and expression of the gene coding for IL-2(60)-PE40, a molecular targeted protein.
    Zhang M; Zhao X; Li H; Lu S
    Chin Med Sci J; 1995 Sep; 10(3):136-40. PubMed ID: 8580481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
    Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGN-10. Seattle Genetics.
    Smith SV
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1314-9. PubMed ID: 11717821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
    Tolcher AW; Sugarman S; Gelmon KA; Cohen R; Saleh M; Isaacs C; Young L; Healey D; Onetto N; Slichenmyer W
    J Clin Oncol; 1999 Feb; 17(2):478-84. PubMed ID: 10080588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
    Francisco JA; Schreiber GJ; Comereski CR; Mezza LE; Warner GL; Davidson TJ; Ledbetter JA; Siegall CB
    Blood; 1997 Jun; 89(12):4493-500. PubMed ID: 9192773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Fc2'-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice.
    Fishman A; Prus D; Belostotsky R; Lorberboum-Galski H
    Clin Exp Immunol; 2000 Mar; 119(3):398-403. PubMed ID: 10691909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BR96-doxorubicin: been there, done that!
    Tolcher AW
    J Clin Oncol; 2000 Dec; 18(23):4000. PubMed ID: 11099337
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical trials with Pseudomonas exotoxin immunotoxins.
    Pai LH; Pastan I
    Curr Top Microbiol Immunol; 1998; 234():83-96. PubMed ID: 9670614
    [No Abstract]   [Full Text] [Related]  

  • 30. Chimeric fusion proteins--Pseudomonas exotoxin-based.
    Kreitman RJ
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.
    Shao Y; Warman BE; Perentesis JP
    Methods Mol Biol; 2001; 166():31-53. PubMed ID: 11217375
    [No Abstract]   [Full Text] [Related]  

  • 32. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
    Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
    Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
    [No Abstract]   [Full Text] [Related]  

  • 33. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).
    Pai LH; Gallo MG; FitzGerald DJ; Pastan I
    Cancer Res; 1991 Jun; 51(11):2808-12. PubMed ID: 2032221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.
    Shinohara H; Fan D; Ozawa S; Yano S; Van Arsdell M; Viner JL; Beers R; Pastan I; Fidler IJ
    Int J Oncol; 2000 Oct; 17(4):643-51. PubMed ID: 10995873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.
    Antignani A; Mathews Griner L; Guha R; Simon N; Pasetto M; Keller J; Huang M; Angelus E; Pastan I; Ferrer M; FitzGerald DJ; Thomas CJ
    PLoS One; 2016; 11(8):e0161415. PubMed ID: 27556570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of anti-HIV immunotoxins.
    Pincus SH
    Antiviral Res; 1996 Dec; 33(1):1-9. PubMed ID: 8955848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant fusion toxins for cancer treatment.
    Kreitman RJ
    Expert Opin Biol Ther; 2002 Dec; 2(8):785-91. PubMed ID: 12517258
    [No Abstract]   [Full Text] [Related]  

  • 39. Peptide toxins directed at the matrix dissolution systems of cancer cells.
    Frankel AE; Bugge TH; Liu S; Vallera DA; Leppla SH
    Protein Pept Lett; 2002 Feb; 9(1):1-14. PubMed ID: 12141918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunotoxins and immunocytokines].
    Contet A; Caussanel V; Beck A; Lowe P
    Med Sci (Paris); 2019 Dec; 35(12):1054-1061. PubMed ID: 31903917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.